Aging of the population is causing an increase in the burden of neurological diseases and creating the need for safe and effective treatments for these disorders. Consequently, the scope of clinical trials for neurological conditions is widening to include biologics, orphan indications and medical devices.
Biomedical research represents in fact a promising approach for the management of neurological diseases, and interest in orphan drugs is increasing thanks to a greater understanding of rare neurological disorders. Moreover, clinical trials are also frequently evaluating devices for neurological disorders, and the number of devices approved by the FDA is in fact 10 times greater than the number of drugs.
These investigations pose unique challenges, and require rigorous methodology and expanded collaboration among industry, investigators, patients and stakeholders.
In a field where the unmet patient needs are huge, OPIS is strongly committed to support the Sponsors with sound scientific, operational and regulatory expertise.
More than 60 studies managed
Indications: Alzheimer’s disease, epilepsy, migraine, multiple sclerosis, Parkinson's disease, post-herpetic neuralgia, vascular dementia
Phases: II, IIb, III, IIIa, IIIb, IV
Other details: interventional and non-interventional studies in adults and children